ANALYSIS: Myriad, Mayo fuel US biotech patent rejections
This article was originally published in Clinica
Executive Summary
Rejections by the US Patent and Trademark Office (US PTO) of applications for biotechnology-related inventions appear to significantly be on the rise after new examination guidelines were put in place following the Supreme Court's rulings in Association for Molecular Pathology v Myriad Genetics and Mayo Collaborative Services v Prometheus Laboratories – two decisions that sent shockwaves through the industry – according to a new report.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.